STOCK WATCH

SHARES in Oxford Biodynamics tumbled after it cast doubt over the financial health of the business.

The biotechnology firm, spun out of Oxford University, reported a revenue of £220,000 in the six months to the end of March. It said it will need to make more sales and possibly raise fresh funds during the rest of 2023.

It wants to increase sales of its flagship blood test which launched in February last year. Shares plunged 18pc, or 3.03p, to 13.8p.